245 related articles for article (PubMed ID: 2253228)
21. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
Chi KH; Kunugi KA; Kinsella TJ
Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
[TBL] [Abstract][Full Text] [Related]
22. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
Reed E; Parker RJ; Gill I; Bicher A; Dabholkar M; Vionnet JA; Bostick-Bruton F; Tarone R; Muggia FM
Cancer Res; 1993 Aug; 53(16):3694-9. PubMed ID: 8339278
[TBL] [Abstract][Full Text] [Related]
23. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
24. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
25. DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
Beland FA
Res Rep Health Eff Inst; 1995 Oct; (72):1-27; discussion 29-39. PubMed ID: 11381742
[TBL] [Abstract][Full Text] [Related]
26. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
27. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ
Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029
[TBL] [Abstract][Full Text] [Related]
28. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
29. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
30. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans.
Wild CP; Hasegawa R; Barraud L; Chutimataewin S; Chapot B; Ito N; Montesano R
Cancer Epidemiol Biomarkers Prev; 1996 Mar; 5(3):179-89. PubMed ID: 8833618
[TBL] [Abstract][Full Text] [Related]
31. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
[TBL] [Abstract][Full Text] [Related]
32. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy.
Perera FP; Motzer RJ; Tang D; Reed E; Parker R; Warburton D; O'Neill P; Albertini R; Bigbee WL; Jensen RH
Cancer Res; 1992 Jul; 52(13):3558-65. PubMed ID: 1319825
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
[TBL] [Abstract][Full Text] [Related]
35. Differential removal of DNA adducts derived from anti-diol epoxides of dibenzo[a,l]pyrene and benzo[a]pyrene in human cells.
Dreij K; Seidel A; Jernström B
Chem Res Toxicol; 2005 Apr; 18(4):655-64. PubMed ID: 15833025
[TBL] [Abstract][Full Text] [Related]
36. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts.
Dijt FJ; Fichtinger-Schepman AM; Berends F; Reedijk J
Cancer Res; 1988 Nov; 48(21):6058-62. PubMed ID: 3167856
[TBL] [Abstract][Full Text] [Related]
37. DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay.
Gyorffy E; Anna L; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Poirier MC; Schoket B
Carcinogenesis; 2004 Jul; 25(7):1201-9. PubMed ID: 15001535
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
39. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]